203 Enterprise Boulevard
About SiteOne Therapeutics
SiteOne Therapeutics, headquartered in Bozeman, Montana with a research team in San Francisco, California, is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (NaV1.7) inhibitors based on naturally occurring small molecules. Given the critical role that NaV1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain.
Founders: Sandip Biswal, Justin Du Bois, David Yeomans, John Mulcahy, and George Milijanich
Founder and CSO: George Miljanich
CEO: Stan E. Abel
15 articles with SiteOne Therapeutics
SiteOne Therapeutics Announces Collaboration and License Agreement with Vertex Pharmaceuticals to Advance NaV1.7 Inhibitors for the Treatment of Pain
SiteOne will be responsible for research and early preclinical development activities; Vertex will be responsible for development, and commercialization.
- Grant award to fund formulation of inhaled therapy for chronic cough - - Cough advisory team includes 4 acclaimed researchers -
SiteOne Therapeutics Announces Initiation of Phase 1 Clinical Trial for its Non-Opioid Analgesic for Acute Pain
SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced that dosing has commenced in the company's Phase 1, dose-escalation study of ST-2427, a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain.
3/26/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
SiteOne Therapeutics Inc., a private biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced the appointment of John Mulcahy, Ph.D., as chief executive officer
SiteOne Announces Award of $5.3M Federal Grant from NIH / NIDA for the Development of a Novel Non-Opioid Analgesic
SiteOne Therapeutics, a privately-held biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced that it has received a Notice of Award from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH
SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Pain
Potential applications in pain associated with ocular surgery, injury, and Dry Eye Syndrome
SiteOne Therapeutics today announced that Scott Braunstein, MD has been appointed to the Company's Board of Directors.
SiteOne Therapeutics today announced the appointment of John Hunter, Ph.D., as Chief Scientific Officer.
SiteOne Therapeutics to Present Research Findings for Selective Small Molecule Nav1.7 Inhibitors at the 2018 World Congress on Pain
SiteOne Anticipates Filing IND for Lead Candidate by Year-End 2018
Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the Advancement of Novel Non-Opioid Pain Therapeutics
SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announces the addition of some of the world's leading medical and scientific experts in the treatment of acute and chronic pain to its Scientific Advisory Board.
SiteOne Therapeutics Announces Abstract Presentation At the Association for Research in Vision and Ophthalmology (ARVO)
SiteOne Therapeutics, Inc., today announced a presentation at the Association for Research in Vision and Opthalmology (ARVO) meeting in Honolulu, Hawaii, April 29 to May 3, 2018.
U.S. Department of Defense Awards Grant to SiteOne Therapeutics, Supporting Research and Development of Selective Small Molecule NaV1.7 Inhibitors as Acute and Chronic Pain Therapeutics
"There is a critical need for non-opioid therapeutics that treat acute and chronic pain effectively, allowing for less reliance on opioids, and reducing the side effects and addiction potential associated with them."
SiteOne Therapeutics Appoints Debra Odink, Ph.D., As Chief Development Officer As The Company Advances Novel Pain Drug Candidates
SiteOne Therapeutics Announces Research and Development Agreement With Amgen to Advance Portfolio of Highly Selective, Potent Inhibitors of NaV1.7 for Acute and Chronic Pain